Applied Radiation Oncology

09/11/2026

Telix Pharmaceuticals Completes Enrollment in BiPASS Study for Prostate Cancer Imaging

📰🔗 https://zurl.co/bDEw6

Telix Pharmaceuticals Ltd. has successfully completed patient enrollment for its Phase 3 BiPASS study involving the PSMA-PET imaging agents Illuccix® and Gozellix®. This study focuses on enhancing prostate cancer diagnosis in the pre-biopsy setting.

09/11/2026

Case Study: Localized Prostate Cancer Recurrence

🔗 https://zurl.co/UeVvY

This report confirms the important clinical consideration of the high sensitivity of Ga-68 PSMA PET/CT in determining disease recurrence after initial treatment failure, particularly in patients with very low PSA levels.

A 70-year-old man presented with persistent rising prostate specific antigen (PSA) of 3.2ng/mL in July 2020. The patient was post retropubic radical prostatectomy (RRP) for Gleason 3+4=7 in 2006. Subsequently, the patient experienced biochemical recurrences for which he received salvage external bea...

09/10/2026

Dose-Escalated Radiotherapy Shows Promise in High-Risk Prostate Cancer Management

📰🔗 https://zurl.co/JhMuA

A recent multicenter study published in The Lancet Oncology has provided insight into the potential benefits of dose-escalated external-beam radiation therapy (EBRT) in conjunction with long-term androgen-deprivation therapy (ADT) for patients with high-risk prostate cancer.

09/10/2026

Robotic-Assisted Seminal Vesicle Excision vs Brachytherapy for Isolated Seminal Vesicle Recurrence: 2 Case Reports

🔗 https://zurl.co/1DdKv

We present 2 cases of ISVR treated with robotic-assisted seminal vesicle excision (RASVE) vs low-dose-rate (LDR) salvage brachytherapy, both of which rendered the patients disease free with undetectable prostate-specific antigen with short-term follow-up.

The most common treatment for isolated seminal vesicle recurrence (ISVR) has been androgen deprivation therapy (ADT). Prior to the introduction of prostate-specific membrane antigen PET (PSMA-PET), detecting ISVR was imprecise, with most patients treated with ADT in the setting of biochemical failur...

09/09/2026

Curious to hear more from radiation oncologist Shearwood McClelland III, MD from the Stephenson Cancer Center at OU Health?

🔗 Check out our interview in the RadOnc Student Scan (Issue 12): https://zurl.co/rXVMD

09/09/2026

CHHiP vs PROFIT for Localized Prostate Cancer: A Retrospective Dosimetric Comparison of Organs at Risk

🔗 https://zurl.co/jkj8N

In our dosimetric comparison, CHHiP spared the OARs to a greater degree than PROFIT. While contouring and planning using the CHHiP protocol are usually more demanding, we expect that greater sparing of OARs will minimize clinical toxicity in patients with prostate cancer receiving moderately hypofractionated radiation therapy.

Moderate hypofractionation for localized prostate cancer has become a standard of care in many radiation therapy centers worldwide. Several fractionation and planning protocols exist, with CHHiP and PROFIT (60 Gy in 20 fractions) being 2 of the most commonly used. We retrospectively compared the dos...

09/08/2026

Study Highlights Limitations of Shorter Radiotherapy in Glioblastoma Treatment

🔗📰 https://zurl.co/bQkyd

The study indicates that this treatment regimen correlates with a significantly shorter median overall survival period compared to the established standard fractionation approach.

Image from ScienceDirect

09/08/2026

Extracapsular Prostate Brachytherapy Using Iodine-125 for Intermediate and Selected High-Risk Prostate Cancer: Technical Notes

🔗 https://zurl.co/vrr6A

The aim is to describe extracapsular prostate brachytherapy (ECPB) techniques using low-dose-rate (LDR) for patients with intermediate-risk prostate cancer (IRPC) and selected high-risk prostate cancer (HRPC).

Our aim is to describe extracapsular prostate brachytherapy (ECPB) techniques using low-dose-rate (LDR) for patients with intermediate-risk prostate cancer (IRPC) and selected high-risk prostate cancer (HRPC).

09/03/2026

Measured Distribution of Total Red Bone Marrow in Young Children

🔗🎗️ https://zurl.co/YFhTB

Pediatric radiation therapy survivors are at risk for radiation-induced hematological malignancies related to red bone marrow (RBM) dose. No measurement-based analysis has been performed to characterize RBM in children. As an exploratory pilot study, we aimed to measure RBM content in children’s subvolumes through total-body MRI.

Background and Purpose: Pediatric radiation therapy survivors incur risk for radiation-induced hematological malignancies related to red bone marrow (RBM) dose. No measurement-based analysis has been performed to characterize RBM in children. As an exploratory pilot study, we aimed to measure RBM co...

09/03/2026

RefleXion X1 Treatment Planning Feasibility Study for Craniospinal Irradiation (CSI)

🔗 https://zurl.co/CReej

The first clinical biology-guided radiation therapy system, RefleXion X1, was commissioned for clinical use at our institution. This study evaluates the X1 treatment planning feasibility of complex craniospinal targets for pediatric medulloblastoma patients and compares plan quality to multi-isocenter linac-based Volumetric Modulated Arc Therapy (VMAT) plans.